C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
11/2006
11/16/2006	WO2006089230A3 Human monoclonal antibodies to prostate specific membrane antigen (psma)
11/16/2006	WO2006072624A3 Compositions and methods for treating viral infection
11/16/2006	WO2006050219A3 Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
11/16/2006	WO2006031370A3 Polypeptide variants with altered effector function
11/16/2006	WO2006029183A3 Compositions and methods for the diagnosis and treatment of tumor
11/16/2006	WO2005103083A3 Anti-cd38 human antibodies and uses therefor
11/16/2006	WO2004108157A8 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
11/16/2006	WO2003087129A3 Immunogenic peptides, and method of identifying same
11/16/2006	WO2003073916A8 Immune regulation
11/16/2006	US20060259993 Amidases, nucleic acids encoding them and methods for making and using them
11/16/2006	US20060258852 strategic modifications of non-human donor antibody amino acids (eg. CDR residues); obtains humanized antibody with low immunogenicity
11/16/2006	US20060258848 Human antipneumococcal antibodies from non-human animals
11/16/2006	US20060258842 Fully humanized monoclonal antibodies that neutralize Bacillus anthracis lethal toxin; vaccines
11/16/2006	US20060258841 Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
11/16/2006	US20060258594 Antibodies to the HIV-1 Tat protein, which bind specifically to a specific epitope found in different HIV-1 strains and subtypes; for use in passive therapy
11/16/2006	US20060258576 Gdnf-related neuropeptides
11/16/2006	US20060258574 Novel compositions and methods for the treatment of psoriasis
11/16/2006	US20060258564 Method for synthesizing conformationally constrained peptides, peptidomimetics and the use thereof as synthetic vaccines
11/16/2006	US20060257989 Truncated aggrecanase molecules
11/16/2006	US20060257975 Encoded by nucleic acid of given sequence; hybridizes to complement of nucleic acid; use as molecular weight markers,
11/16/2006	US20060257972 Purification of human monoclonal antibody and human polyclonal antibody
11/16/2006	US20060257971 Antibodies to pro1561 polypeptide
11/16/2006	US20060257965 Extracellular matrix signalling molecules
11/16/2006	US20060257953 Artificial antibody polypeptides
11/16/2006	US20060257948 determining whether a treatment of a disorder with an HDAC inhibitor is to be started/continued or not by determining the level of histone acetylation in the sample using an antibody capable of binding to acetylated histone
11/16/2006	US20060257937 Focused libraries of genetic packages
11/16/2006	US20060257928 ANGE gene in atopy
11/16/2006	US20060257927 Processes for purification of recombinant proteins
11/16/2006	US20060257925 Method for isolating intracellular antibodies able to neutralize protein interactions
11/16/2006	US20060257911 Of given nucleotide sequence; diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders
11/16/2006	US20060257897 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/16/2006	US20060257882 Novel polynuceotides and polypeptides encoded thereby
11/16/2006	US20060257880 Gastric and prostate cancer associated antigens
11/16/2006	US20060257859 Recombinant enterovirus 71 neutralizing antibodies and applications thereof
11/16/2006	US20060257856 Heterodimeric receptor libraries using phagemids
11/16/2006	US20060257852 Severe acute respiratory syndrome coronavirus
11/16/2006	US20060257427 Molecule (antibody, peptide or chemical), coupled to a detectable label, cytotoxic agent or solid support, that specifically binds an extracellular portion of the latent viral membrane bound protein of Epstein-Barr Virus expressed in the latent viral membrane in the latent life cycle
11/16/2006	US20060257418 Vaccine
11/16/2006	US20060257417 Vaccine antigens of Moraxella
11/16/2006	US20060257412 Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
11/16/2006	US20060257409 Breast Specific Genes and Proteins
11/16/2006	US20060257407 Anti-IL-6 antibodies, compositions, methods and uses
11/16/2006	US20060257406 Immunoglobulin variable domain; tumor necrosis factor; competitve binding; surface plasmon resonance
11/16/2006	US20060257404 Modulators of the P2Y10 receptor useful in altering T lymphocyte function
11/16/2006	US20060257398 humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker; B-cell malignancies and autoimmune diseases
11/16/2006	US20060257397 Human binding molecule against CD1A
11/16/2006	US20060257394 Modified antibody fab fragments
11/16/2006	US20060257393 Method for protecting thiol group of protein
11/16/2006	US20060257361 Novel form of interleukin-15, Fc-IL-15, and methods of use
11/16/2006	US20060257318 Method for the in vitro assessment of the progression status of an infection by an hiv virus in an individual
11/16/2006	CA2651376A1 Method for diagnosis and treatment of a mental disease
11/16/2006	CA2608315A1 Use of a new gene coding for a new member of the mcm2-8 family in pharmaceutical compositions
11/16/2006	CA2608195A1 Nebulization of monoclonal antibodies for treating pulmonary diseases
11/16/2006	CA2608058A1 Host cell specific binding molecules capable of neutralizing viruses and uses thereof
11/16/2006	CA2607588A1 Il-31 monoclonal antibodies and methods of use
11/16/2006	CA2607281A1 Anti-cd19 antibody therapy for autoimmune disease
11/16/2006	CA2607147A1 Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
11/16/2006	CA2607082A1 Immunoglobulin fraction and process therefor
11/16/2006	CA2607044A1 Cardiovascular disease therapies
11/16/2006	CA2606778A1 Vascular disease therapies
11/16/2006	CA2606287A1 Peptide
11/15/2006	EP1722231A2 Method for identification of somatic stem cells
11/15/2006	EP1722230A2 Method for detection of a disease-specific combinatorial molecular pattern motif in a tissue sample of a patient's skin
11/15/2006	EP1721985A1 Nucleic acid construct containing full-length genome of human hepatitis c virus, recombinant full-length virus genome replicative cell having the nucleic acid construct transferred thereinto and method of constructing hepatitis c viral particles
11/15/2006	EP1721979A1 Compositions and methods for increasing bone mineralisation
11/15/2006	EP1721978A1 Nucleotide sequences coding for alpha chain variable regions in human lymphocyte receptors and applications thereof
11/15/2006	EP1721977A2 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
11/15/2006	EP1721972A2 Telomere protein trf2 dna-binding domain mutant protein, telomere dna mutant and utilization of complex structure of trf2 dna-binding domain with double-stranded dna
11/15/2006	EP1721909A1 Growth factor mutants with altered biological attributes
11/15/2006	EP1721609A2 Pyridylpyrimidine derivatives as effective compounds against prion infections and prion diseases
11/15/2006	EP1721162A1 Method of assessing rheumatoid arthritis by measuring anti-ccp and serum amyloid a
11/15/2006	EP1721157A1 Use of tweak modulators and inhibitors for the treatment of neurological conditions
11/15/2006	EP1720997A1 Methods to make and use antibodies of improved cross-reactivity
11/15/2006	EP1720910A2 Method and composition for angiogenesis inhibition
11/15/2006	EP1720909A2 Anti-abeta antibody
11/15/2006	EP1720908A2 Super-humanized antibodies against respiratory syncytial virus
11/15/2006	EP1720907A2 Anti-cd38 human antibodies and uses therefor
11/15/2006	EP1720906A2 Antibody compositions and methods
11/15/2006	EP1720902A1 Mutein of a bone morphogenetic protein and use thereof
11/15/2006	EP1720893A2 Compositions and methods for the systemic treatment of arthritis
11/15/2006	EP1720575A2 Therapeutic and diagnostic conjugates for use with multispecific antibodies
11/15/2006	EP1720574A1 Method of treating abnormal cell growth using c-met and-tor inhibitors
11/15/2006	EP1720573A2 Methods and compositions for treating il-13 related pathologies
11/15/2006	EP1720572A1 Monovalent ligand of the fcalphari receptor as an anti-inflammatory agent
11/15/2006	EP1720571A2 Method of treating hemolytic disease
11/15/2006	EP1720570A2 Treatment of dengue hemorrhagic fever
11/15/2006	EP1720569A1 Target for b-cell disorders
11/15/2006	EP1615996A4 Uses of vascular endothelial growth factor and type i collagen inducible protein (vcip)
11/15/2006	EP1547612A4 Medicinal agent and method for curing erectile dysfunction
11/15/2006	EP1434856A4 Activation and expansion of cells
11/15/2006	EP1407014B1 Screening method for attenuating or virulence defective microbial cells
11/15/2006	EP1283869B1 Novel bee venom polypeptides and methods of use thereof
11/15/2006	EP1206493B1 Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
11/15/2006	EP1198560B1 Mammalian adhesion protease
11/15/2006	EP1064372B1 Compounds and methods for therapy and diagnosis of lung cancer
11/15/2006	EP1047793B1 Biomarkers and targets for diagnosis, prognosis and management of prostate disease
11/15/2006	CN1864068A Methods for reducing complexity of a sample using small epitope antibodies
11/15/2006	CN1863921A Methods for expression and purification of immunotoxins
11/15/2006	CN1863818A Anti-VEGF antibodies
11/15/2006	CN1863817A Antibodies to M-CSF

1 ... 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 ... 1494